|
| Press Releases |
|
 |
|
| Friday, October 21, 2016 |
|
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
| Tuesday, September 20, 2016 |
|
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
| Wednesday, September 14, 2016 |
|
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
| Thursday, July 7, 2016 |
|
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
| Tuesday, May 31, 2016 |
|
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
| Friday, April 29, 2016 |
|
|
Nanobiotix: 2015 Annual Results |
| Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
| Tuesday, January 5, 2016 |
|
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
| Thursday, July 2, 2015 |
|
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
| Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
| Wednesday, June 10, 2015 |
|
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cornerstone Robotics Completes the World's First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery 
Aug 6, 2025 19:21 HKT/SGT
|
|
|
Fastport eQuad, Flagship Product from New Honda Business Venture, Wins "Red Dot: Best of the Best 2025" Award in Red Dot Award: Design Concept
Aug 6, 2025 19:40 JST
|
|
|
Phoenitron's E-commerce Business records unaudited aggregated profit before taxation of approximately HK$55.6 million in 1H2025
Aug 6, 2025 18:09 HKT/SGT
|
|
|
Dream Incubator and DENSO Launch Demonstration Project for Digital Platform Development for Mobility Circular Economy and Integrated Manufacturing for India
Aug 6, 2025 18:54 JST
|
|
|
International Land Alliance Brings Baja to Buyers with Live Zoom Webinar Experience
Aug 6, 2025 17:32 HKT/SGT
|
|
|
Luxren Capital Rolls Out High-Performance Mobile Trading App for Global Users
Aug 6, 2025 17:00 HKT/SGT
|
|
|
MyFintech Week 2025 Highlights Transformative Forces in Finance
Aug 6, 2025 17:00 HKT/SGT
|
|
|
HKTDC appoints Sophia CHONG as Executive Director
Aug 6, 2025 16:56 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 6, 2025 16:35 HKT/SGT
|
|
|
iFex Capital Launches Major Mobile Trading App Overhaul to Meet Surging Demand
Aug 6, 2025 16:00 HKT/SGT
|
|
|
35th Food Expo opens next week five theme days kick off premium lifestyle journey
Aug 6, 2025 15:05 HKT/SGT
|
|
|
AITO launches EV Road Tour from Chongqing to Jakarta
Aug 6, 2025 14:22 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 6, 2025 13:20 HKT/SGT
|
|
|
University of Cyberjaya Welcomes Education Reforms under RMK13: A Bold Step Toward Future-Ready Talent and Inclusive Innovation
Aug 6, 2025 12:27 HKT/SGT
|
|
|
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
Aug 6, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
